Trial Profile
Evaluation of the safety and pharmacokinetics and determining the maximum tolerable dose with the use of antitumor peptide CIGB-552 in solid tumors. Phase I.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs CIGB 552 (Primary)
- Indications Cancer metastases; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms ARGOS-1
- 15 Sep 2021 Status changed to completed, according to Results published in the International Journal of Cancer
- 15 Sep 2021 Results published in the International Journal of Cancer
- 29 Feb 2016 New trial record